Physician profile
Jamie T Brogan
NPI 1295151967
$281,875.17
in general payments reported to CMS, 2019-2025
16 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,204 · 2022: $21K · 2023: $64K · 2024: $84K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $156K · Travel and Lodging: $57K · Consulting Fee: $34K · Food and Beverage: $8,222 · Honoraria: $810 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,374.86 |
| Travel and Lodging | $56,790.64 |
| Consulting Fee | $33,743.13 |
| Food and Beverage | $8,222.02 |
| Honoraria | $810.00 |
| Education | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $148,503.30 | 2022-2025 | Tremfya, Stelara |
| Abbvie INC. | $73,446.30 | 2021-2025 | |
| Lilly USA, LLC | $32,129.18 | 2022-2025 | Omvoh, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,548.90 | 2022-2024 | Cyltezo |
| Takeda Pharmaceuticals U.S.A., INC. | $7,111.48 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $4,447.89 | 2022-2025 | |
| Evoke Pharma, INC. | $1,990.03 | 2021 | |
| Celltrion USA INC. | $1,902.94 | 2025 | Zymfentra, Vegzelma |
| Fresenius Kabi USA, LLC | $1,628.91 | 2023 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $819.83 | 2021-2022 | |
| Celgene Corporation | $687.41 | 2021-2024 | Zeposia |
| Shield Therapeutics INC | $480.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.25 | 2022-2023 | |
| Exact Sciences Corporation | $43.77 | 2023 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $31.15 | 2024 | Stelara |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14.83 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Brogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.